DENVER, July 18, 2006 (PRIMEZONE) -- Chelsea Management Group Inc. (Other OTC:CLMP) has commenced initial market testing of Psoriasis Complex 7003. The all natural product offers proven efficacy for skin conditions such as acne, rosaceous and psoriasis.
In studies, Complex 7003 has proven to be up to 50% more effective in comparison to pharmaceutical and cosmetic products in reducing inflammation. In a Vivo Test carried out on two panels of 50 volunteers, Complex 7003 again improved the clinical signs of skin sensitivity by more than 60% over a 28-day period versus a placebo.
Chelsea Management is sending a sample of the product to a select group for trial use. It is our intention to use the feedback received for future marketing campaigns. Also, we are currently searching for a suitable trade name for the product. Chelsea welcomes any product name suggestions from existing shareholders.
About Chelsea Management Group Inc.
Chelsea Management Group is a start-up and early-stage venture capital firm focused on the health and life sciences industry. Formed in 2001, Chelsea searches for the winners of tomorrow -- entrepreneurs whose ideas and talents qualify them to pursue large market opportunities successfully. We seek opportunities across a broad spectrum, including biotechnology and pharmaceuticals, medical devices, services and healthcare/life sciences information technology. On a selective basis, we also consider later-stage health and life sciences investments where we can uniquely apply Chelsea's industry and capital markets experience.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this release that are forward-looking statements are based on current expectations and assumptions that are subject to known and unknown risks, uncertainties, or other factors which may cause actual results, performance, or achievements of the company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Actual results could differ materially because of factors such as the effect of general economic and market conditions, entry into markets with vigorous competition, market acceptance of new products and services, continued acceptance of existing products and services, technological shifts, and delays in product development and related product release schedules, any of which may cause revenues and income to fall short of anticipated levels. All information in this release is as of the date of this release. The company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.